|
000
| 01955nam 2200301za 4500 |
|---|
| 001 | 9.847509 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107153446 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 171121s2018 onc o f000 0 eng d |
|---|
| 020 | |a9780660239293|z9780660239309 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aNR16-172/2017E-PDF |
|---|
| 245 | 00|aSynthetic archaeosome adjuvants for improved vaccine formulation (L-11784) |h[electronic resource]. |
|---|
| 260 | |a[Ottawa] : |bNational Research Council Canada, |c[2018] |
|---|
| 300 | |a[1] p. |
|---|
| 500 | |aIssued also in French under title: Adjuvants d’archéosomes synthétiques pour améliorer la préparation de vaccins (L-11784). |
|---|
| 500 | |aCaption title. |
|---|
| 500 | |a"January 2017." |
|---|
| 520 | |a“Vaccine adjuvants are immune stimulating compounds that, when combined with antigens, enhance the magnitude, the quality and/or the duration of immune responses. Though adjuvants play a central role in vaccination, few non-toxic adjuvants are currently available to vaccine developers. To address this need, the NRC has developed synthetic archaeal lipids for the production of well-defined, tailor-made, non-toxic and thermostable adjuvants that can be can combined with a wide range of antigens. The NRC’s synthetic archaeosomes have both immunomodulating and antigen-delivery adjuvant properties. They can be customized to evoke specific immune responses that are long and durable”--Highlights. |
|---|
| 530 | |aIssued also in print format. |
|---|
| 693 | 4|aImmunological adjuvants |
|---|
| 693 | 4|aLiposomes |
|---|
| 710 | 2 |aNational Research Council Canada. |
|---|
| 775 | 08|tAdjuvants d’archéosomes synthétiques pour améliorer la préparation de vaccins (L-11784) |w(CaOODSP)9.847512 |
|---|
| 776 | 0#|tSynthetic archaeosome adjuvants for improved vaccine formulation |w(CaOODSP)9.847511 |
|---|
| 856 | 40|qPDF|s116 KB|uhttps://publications.gc.ca/collections/collection_2018/cnrc-nrc/NR16-172-2017-eng.pdf |
|---|